Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
CTX-310 by CRISPR Therapeutics for Hypertriglyceridemia: Likelihood of Approval
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II...
CTX-310 by CRISPR Therapeutics for Mixed Dyslipidemia: Likelihood of Approval
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Mixed Dyslipidemia. According to GlobalData, Phase...
CTX-310 by CRISPR Therapeutics for Homozygous Familial Hypercholesterolemia (HoFH): Likelihood of Approval
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Homozygous Familial Hypercholesterolemia (HoFH). According to...
CTX-310 by CRISPR Therapeutics for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval
CTX-310 is under clinical development by CRISPR Therapeutics and currently in Phase II for Heterozygous familial hypercholesterolemia (heFH). According to...